1. Home
  2. FATE vs ACOG Comparison

FATE vs ACOG Comparison

Compare FATE & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • ACOG
  • Stock Information
  • Founded
  • FATE 2007
  • ACOG 2000
  • Country
  • FATE United States
  • ACOG Canada
  • Employees
  • FATE N/A
  • ACOG N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • ACOG
  • Sector
  • FATE Health Care
  • ACOG
  • Exchange
  • FATE Nasdaq
  • ACOG Nasdaq
  • Market Cap
  • FATE 116.5M
  • ACOG 129.6M
  • IPO Year
  • FATE 2013
  • ACOG N/A
  • Fundamental
  • Price
  • FATE $1.47
  • ACOG $6.80
  • Analyst Decision
  • FATE Hold
  • ACOG Strong Buy
  • Analyst Count
  • FATE 6
  • ACOG 1
  • Target Price
  • FATE $3.30
  • ACOG $20.00
  • AVG Volume (30 Days)
  • FATE 3.1M
  • ACOG 92.2K
  • Earning Date
  • FATE 11-11-2025
  • ACOG 11-14-2025
  • Dividend Yield
  • FATE N/A
  • ACOG N/A
  • EPS Growth
  • FATE N/A
  • ACOG N/A
  • EPS
  • FATE N/A
  • ACOG N/A
  • Revenue
  • FATE $8,470,000.00
  • ACOG $4,586,341.00
  • Revenue This Year
  • FATE N/A
  • ACOG N/A
  • Revenue Next Year
  • FATE N/A
  • ACOG $149.89
  • P/E Ratio
  • FATE N/A
  • ACOG N/A
  • Revenue Growth
  • FATE N/A
  • ACOG N/A
  • 52 Week Low
  • FATE $0.66
  • ACOG $3.75
  • 52 Week High
  • FATE $3.50
  • ACOG $11.54
  • Technical
  • Relative Strength Index (RSI)
  • FATE 62.81
  • ACOG 38.48
  • Support Level
  • FATE $1.30
  • ACOG $6.80
  • Resistance Level
  • FATE $1.65
  • ACOG $7.83
  • Average True Range (ATR)
  • FATE 0.17
  • ACOG 0.51
  • MACD
  • FATE 0.02
  • ACOG 0.00
  • Stochastic Oscillator
  • FATE 73.77
  • ACOG 34.39

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: